COVID-19: TCM Lianhua Qingwen speeds up recovery but no effect in preventing conversion to severe cases – two-week RCT
A two-week clinical trial led by renowned Chinese pulmonologist Zhong Nanshan showed that consuming the botanical TCM product Lianhua Qingwen (LH) capsules and undergoing the standard therapy can speed up recovery in COVID-19 patients.
However, it has not proved to be effective in preventing severe infection from happening or reducing median viral assay conversion time.
In the trial which took place from Feb 2 to 15, nine in 10 of the subjects (91.5%) in the treatment group had completely recovered from at least one major symptom, such as coughing, fever, and fatigue by the end of the trial.
The recovery rate in the control group was 82.4%. The result was statistically significant with a p-value of less than 0.05 at 0.022.
![Beauty consumers are most likely to prioritise devices and treatments as solution over supplements. [Getty Images]](/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_tiny/publications/cosmetics/cosmeticsdesign-asia.com/headlines/market-trends/beauty-supplements-consumers-likely-to-explore-devices-treatments-before-supplements/17712040-1-eng-GB/Beauty-supplements-Consumers-likely-to-explore-devices-treatments-before-supplements.jpg)
